CHIRP试验:高危前列腺癌常规分割与中度大分割放疗联合盆腔淋巴结照射的II期随机对照研究
CHIRP是一项II期前瞻性随机试验,纳入111例高危前列腺癌患者,随机接受前列腺+盆腔淋巴结HFRT(68 Gy/25次)或CFRT(78 Gy/39次)联合18个月雄激素抑制治疗。结果显示两组急性和晚期GI/GU毒性均无显著差异,3年生化无复发生存率和总生存率亦无显著差异。
要点
- HFRT与CFRT在高危前列腺癌盆腔淋巴结照射中急性和晚期GI/GU毒性无显著差异。
- 两组3年生化无复发生存率(HFRT 97.3% vs CFRT 91.0%)和总生存率无显著差异。
核心结论
- HFRT与CFRT用于高危前列腺癌前列腺及盆腔淋巴结照射均耐受良好,3年生化无复发生存率和总生存率相似。
研究设计与样本
- II期前瞻性随机对照试验,2012至2018年纳入111例高危前列腺癌患者,109例接受治疗,按意向性分析。
- 患者随机接受HFRT(68 Gy/25次)或CFRT(78 Gy/39次)前列腺+盆腔淋巴结放疗,联合18个月雄激素抑制治疗。
- 毒性采用CTCAE 4.0评分,生化失败采用Phoenix定义,中位随访38.0个月(范围4.8-77.8个月)。
主要发现
- 急性GU毒性HFRT 30.2% vs CFRT 30.9%(P=1.00),无显著差异。
临床怎么用
- 对于高危前列腺癌需前列腺及盆腔淋巴结照射的患者,HFRT(68 Gy/25次)可作为CFRT(78 Gy/39次)的可行替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypofractionated radiation therapy (HFRT) may offer treatment advantages for patients with prostate cancer. However, HFRT may also increase the risk of gastrointestinal (GI) or genitourinary (GU) toxicity compared with conventionally fractionated radiation therapy (CFRT). Several large trials have found that HFRT is well tolerated in mixed risk population studies. Here, we report on a phase II, randomized controlled study conducted to evaluate these endpoints in exclusively high-risk patients with prostate cancer treated with prostate and pelvic nodal radiation. METHODS AND MATERIALS: After giving informed consent, patients with high-risk prostate cancer were randomly assigned to prostate plus pelvic nodal radiation therapy with either HFRT (68 Gy in 25 fractions) or CFRT (78 Gy in 39 fractions) and 18 months of androgen suppression therapy. Toxicity was scored using the Common Terminology Criteria for Adverse Events (version 4.0). Biochemical failure was determined by the Phoenix definition. Patients were analyzed on an intention-to-treat basis. RESULTS: From 2012 to 2018, 111 patients with high-risk prostate cancer were enrolled and 109 patients were treated. The cumulative incidence of grade 2 or higher acute GI toxicity was not significantly different between the arms (HFRT 18.9% vs CFRT 21.8%; P = .812). Similarly, acute GU (HFRT 30.2% vs CFRT 30.9%; P = 1.00), late GI (HFRT 16.0% vs CFRT 10.0%; P = .554), and late GU (HFRT 16.0% vs CFRT 6.0%; P = .200) were not significantly different between the arms. Median follow-up was 38.0 months (4.8-77.8 months). The 3-year biochemical recurrence-free survival was not significantly different between the 2 arms (97.3% for HFRT vs 91.0% for CFRT; P = .606). The 3-year overall survival was 94.8% in the HFRT arm and 100.0% in the CFRT arm (P = .116). CONCLUSIONS: HFRT and CFRT using intensity modulated radiation therapy were both well tolerated for patients with high-risk prostate cancer and resulted in similar 3-year biochemical recurrence-free survival and overall survival.
引用
- Wang MH, Vos LJ, Yee D, et al. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer. Pract Radiat Oncol. 2021. PMID: 33705985. doi:10.1016/j.prro.2021.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。